Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 1/20 | 0.34 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | APP | P05067 | 1/20 | 0.32 |
| ▸ | NEK1 | Q96PY6 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | ESR1 | P03372 | 1/20 | 0.31 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.31 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21160614 | 0.79 | APP (0.40) | EGFRNTSR1L3MBTL1MAPK1APP | |
| SCHEMBL21037446 | 0.76 | ALDH1A1 (0.34) | EGFRL3MBTL1APPESR1ESR2 | |
| SCHEMBL21160618 | 0.75 | GPR35 (0.33) | MAPK1KDM4EALDH1A1 | |
| SCHEMBL21037456 | 0.71 | APP (0.43) | EGFRAPPMAPTALDH1A1 | |
| SCHEMBL1568157 | 0.68 | GPR35 (0.39) | MAPTALDH1A1 | |
| SCHEMBL21160411 | 0.68 | GPR35 (0.39) | L3MBTL1MAPK1TDP1KDM4EALDH1A1 | |
| SCHEMBL21160451 | 0.68 | PDE10A (0.43) | EGFRL3MBTL1MAPK1TDP1MAP4K4 | |
| SCHEMBL20718257 | 0.66 | BCKDK (0.42) | MAPTLMNAKDM4EALDH1A1 | |
| SCHEMBL14925152 | 0.65 | GPR35 (0.37) | MAPT | |
| SCHEMBL21160615 | 0.65 | CLK1 (0.43) | L3MBTL1APPMAP4K4MAPTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11209437-B2 | Fluorescent probe and preparation method and use thereof | FLUORESCENCE DIAGNOSIS (SHANGHAI) BIOTECH COMPANY (CN) | 2021-12-28 | — | — | US | disclosed |
| US-20190187144-A1 | FLUORESCENT PROBE AND PREPARATION METHOD AND USE THEREOF | EAST CHINA UNIVERSITY OF SCIENCE AND TECHNOLOGY (CN) | 2019-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190187144-A1 | FLUORESCENT PROBE AND PREPARATION METHOD AND USE THEREOF | HNRNPF, HNRNPUL2, RAB5IF | EGFR 3881/4885NTSR1 3903/4885L3MBTL1 616/4885 |
| US-11209437-B2 | Fluorescent probe and preparation method and use thereof | HNRNPF, HNRNPUL2, RAB5IF | EGFR 3881/4885NTSR1 3903/4885L3MBTL1 616/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.